ANTIMICROBIAL RESISTANCE: PHARMACOLOGICAL AND PUBLIC HEALTH CRISIS

Dr. Krishna Badal, MBBS, MD
Associate Professor, Department of Pediatrics
Faculty of International Students, Asia International University

Abstract. Antimicrobial resistance (AMR) has emerged as a multifaceted crisis, threatening the efficacy of existing antimicrobial agents and undermining modern healthcare achievements. The evolution of resistance mechanisms, driven primarily by antimicrobial misuse and inadequate diagnostics, has accelerated the emergence of multidrug-resistant pathogens. Recent global estimates indicate that one in six bacterial infections is now resistant to commonly used antibiotics[1]. This review synthesizes recent surveillance data, clinical findings, and pharmacological insights to highlight current resistance trends, underlying mechanisms, and implications for public health. Strategies for mitigation, including antimicrobial stewardship, surveillance systems, and innovation in therapeutics, are discussed, emphasizing the urgent need for coordinated global action.

Keywords: Antimicrobial, Resistance, Pharmacology, Public Health, Crisis

1. Introduction

Antimicrobial resistance (AMR) occurs when microorganisms develop the ability to survive exposure to antimicrobial agents that were previously effective. It affects bacteria, viruses, fungi, and parasites and threatens the success of routine medical procedures such as surgery, chemotherapy, and neonatal care[1]. According to the World Health Organization (WHO), AMR is among the top ten global public health threats facing humanity[1].

Global surveillance data demonstrate a steady increase in resistance across multiple pathogen–antibiotic combinations, particularly among Gram-negative bacteria[1,4]. The unchecked rise of AMR risks reversing decades of medical progress and poses a serious challenge to healthcare systems worldwide.

2. Pharmacological Mechanisms Underlying Antimicrobial Resistance

Resistance to antimicrobial agents arises through several well-established pharmacological mechanisms. One of the most common mechanisms is enzymatic drug inactivation, such as the production of β-lactamases that degrade β-lactam antibiotics[2,3]. Another important mechanism is modification of drug targets, which reduces the binding affinity of antimicrobial agents[2].

Additionally, efflux pumps actively expel drugs from microbial cells, lowering intracellular drug concentrations and reducing efficacy[3]. Reduced membrane permeability, particularly in Gram-negative organisms, further limits drug entry. Biofilm formation creates a protected environment in which microorganisms exhibit markedly reduced susceptibility to antimicrobial agents[3].

These mechanisms frequently coexist, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) organisms[2].

3. Clinical and Public Health Impact

3.1 Global Trends in Antimicrobial Resistance

Data from the WHO Global Antimicrobial Resistance Surveillance System (GLASS) indicate that resistance has increased in over 40% of monitored pathogen–antibiotic combinations between 2018 and 2023[1]. High resistance rates have been observed for commonly used antibiotics such as fluoroquinolones, third-generation cephalosporins, and carbapenems[1,4].

Gram-negative pathogens, including *Escherichia coli* and *Klebsiella pneumoniae*, show particularly alarming resistance trends, significantly limiting therapeutic options[1,3].

3.2 Regional Variations

The burden of AMR varies considerably across regions. Low- and middle-income countries report higher resistance rates due to limited diagnostic capacity, widespread over-the-counter antibiotic use, and inadequate regulation[1,5]. Surveillance data from Asia show increasing carbapenem resistance among *K. pneumoniae*, with rates exceeding 25% in some settings[3].

In Europe, although methicillin-resistant *Staphylococcus aureus* (MRSA) rates have declined, carbapenem-resistant Enterobacterales have increased substantially[4].

3.3 Clinical Consequences

AMR leads to higher morbidity and mortality, prolonged hospital stays, and increased healthcare costs[2,6]. Resistant infections are associated with higher rates of treatment failure, intensive care unit admission, and death, particularly among vulnerable populations such as neonates and immunocompromised patients[6].

4. Evidence from Recent Studies

Recent hospital-based studies from India report resistance rates exceeding 80% for commonly prescribed antibiotics such as ciprofloxacin and ampicillin against *E. coli* isolates[5]. Surveillance studies from China and Pakistan demonstrate rising prevalence of MDR and XDR organisms in respiratory and bloodstream infections[3,6].

These findings underscore the urgent need for improved antimicrobial stewardship and strengthened surveillance systems at both national and global levels[1,4].

Table 1. Selected recent studies on antimicrobial resistance (2023–2025)

Study / Source	**Setting**	**Pathogens & Drugs**	**Key Findings**
WHO GLASS Report (2025)[1]	Global surveillance	E. coli, K. pneumoniae, Staph. aureus	One in six infections resistant; >40% increase in resistance across multiple antibiotics; high Gram-negative resistance.
CHINET Surveillance (2024)[2]	China	E. coli, Klebsiella, P. aeruginosa	Rising carbapenem resistance (K. pneumoniae ~22–26%); MRSA ~28% of isolates.
EU EARS-Net (2024)[3]	EU/EEA Countries	MRSA, cephalosporin-resistant E. coli	MRSA incidence decreasing, but carbapenem-resistant K. pneumoniae increased >60% compared to 2019.
Regional Hospital Data – Jaipur (2025)[4]	India	Ciprofloxacin & others vs E. coli, Klebsiella	Ciprofloxacin ineffective in 84% of E. coli isolates; ampicillin resistance ~93%.

Respiratory Infections Study (2023–24)[5]	Pakistan	MDR/XDR respiratory pathogens	High prevalence of MDR/XDR respiratory isolates with significant impact on ICU admissions and mortality.

5. Drivers of Antimicrobial Resistance

5.1 Inappropriate Use of Antimicrobials

The overuse and misuse of antibiotics in human medicine remain major drivers of resistance[2]. Empirical prescribing without microbiological confirmation and patient non-adherence to treatment regimens accelerate the selection of resistant strains[2].

5.2 Agricultural and Veterinary Use

The widespread use of antimicrobials in livestock for growth promotion and disease prevention contributes significantly to environmental reservoirs of resistance, facilitating transmission to humans[1,2].

5.3 Inadequate Diagnostics and Surveillance

Limited access to rapid and accurate diagnostic tools leads to unnecessary antimicrobial exposure. Despite progress, nearly half of countries lack comprehensive national AMR surveillance systems[1].

6. Strategies to Mitigate Antimicrobial Resistance

6.1 Antimicrobial Stewardship

Antimicrobial stewardship programs have demonstrated effectiveness in optimizing antibiotic use, reducing resistance rates, and improving patient outcomes[2]. These programs emphasize appropriate prescribing, dose optimization, and duration control.

6.2 Surveillance and Global Coordination

Global initiatives such as WHO-GLASS and regional networks like EARS-Net play a critical role in monitoring resistance trends and guiding policy decisions[1,4].

6.3 Innovation in Therapeutics and Diagnostics

The slow pace of new antibiotic development necessitates renewed investment in drug discovery, alternative therapies, and rapid diagnostics[7]. WHO has identified priority research areas to address critical gaps in the AMR response[7].

6.4 One Health Approach

The One Health approach integrates human, animal, and environmental health sectors to address AMR comprehensively. Coordinated interventions across these domains are essential for sustainable control of resistance[1,7].

7. Conclusion

Antimicrobial resistance represents a profound pharmacological and public health crisis. Rising resistance rates threaten the effectiveness of existing antimicrobial agents and place immense strain on healthcare systems globally. Evidence from surveillance and clinical studies highlights the urgent need for sustained stewardship, strengthened surveillance, innovation in therapeutics, and global cooperation. Without immediate and coordinated action, the world risks entering a post-antibiotic era with devastating consequences for public health.

References.

1. World Health Organization. Global antibiotic resistance surveillance report 2025: first global estimates of antimicrobial resistance. Geneva: World Health Organization; 2025.

2. Reza N, Shallcross L, Holmes A, et al. Antimicrobial use and resistance. BMJ. 2025;391:e082681.

3. Zhang R, Liu Y, Wang Z, et al. CHINET surveillance of antimicrobial resistance among clinical isolates in China, 2024. One Health Adv. 2025;3:92.

4. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net): annual epidemiological report for 2024. Stockholm: ECDC; 2025.

5. Sharma R, Gupta P, Meena S, et al. Rising antimicrobial resistance patterns in tertiary care hospitals: findings from SMS Hospital, Jaipur. Times of India. 2025.

6. Khan MA, Ahmed S, Ali S, et al. Prevalence and clinical impact of multidrug-resistant and extensively drug-resistant respiratory pathogens in hospitalized patients. J Infect Dev Ctries. 2024;18(11):1452-1460.

7. World Health Organization. WHO outlines 40 research priorities on antimicrobial resistance. Geneva: World Health Organization; 2023.